<DOC>
	<DOCNO>NCT00996021</DOCNO>
	<brief_summary>This randomize , partial-blind , placebo-controlled , single dose , cross-over trial investigate effect GSK1349572 cardiac repolarization compare placebo healthy adult male female . Approximately 42 subject enrol study admit clinic three separate dose session . Subjects receive single dose administration placebo , supratherapeutic dose GSK1349572 ( 250 mg ) , moxifloxacin ( 400 mg ) random sequence . Safety subject monitored clinical observation , measure vital sign , 12-lead ECGs clinical laboratory measurement .</brief_summary>
	<brief_title>Study Assess Cardiac Conduction GSK1349572</brief_title>
	<detailed_description />
	<mesh_term>Dolutegravir</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>AST , ALT , alkaline phosphatase bilirubin ≤ 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . Male female 18 55 year age inclusive , time signing informed consent . A female subject eligible participate Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea [ Childbearing potential agree use one contraception method list protocol appropriate period time ( determined product label investigator ) prior start dose sufficiently minimize risk pregnancy point . Female subject must agree use contraception 3 day last dose study drug . Body weight ≥ 50 kg men ≥ 45 kg woman BMI within range 18.531.0 kg/m2 ( inclusive ) . Capable give write informed consent , include compliance requirement restriction list consent form . The subject positive prestudy drug/alcohol screen . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . History sensitivity study medication , component thereof , history drug allergy . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day prior first dose study medication . If heparin use PK sample , subject history sensitivity heparin heparininduced thrombocytopenia enrol . History regular alcohol consumption within 6 month study define : An average weekly intake &gt; 14 drinks/week men &gt; 7 drinks/week woman . Has history regular use tobacco nicotinecontaining product within 3 month prior screen . Consumption red wine , seville orange , grapefruit grapefruit juice 7 day prior first dose study medication . Pregnant female determine positive serum urine human chorionic gonadotrophin ( hCG ) test screen prior dosing . Lactating female . Unwillingness inability follow procedure outline protocol . Subjects preexist condition interfere normal gastrointestinal anatomy motility , hepatic and/or renal function , could interfere absorption , metabolism , and/or excretion study drug . Subjects history cholecystectomy , inflammatory bowel disease pancreatitis exclude . Subjects active peptic ulcer disease . Subjects history upper gastrointestinal bleeding , History/evidence symptomatic arrhythmia , angina/ischemia , coronary artery bypass grafting ( CABG ) surgery percutaneous transluminal coronary angioplasty ( PCTA ) clinically significant cardiac disease . Personal family history long QT syndrome . History/evidence clinically significant pulmonary disease . History significant renal hepatobiliary disease . Subjects history nephrolithiasis exclude . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . A positive test HIV antibody . History 2nd degree high AV block . History Gilbert 's disease . Where participation study would result donation blood blood product excess 500 mL within 56 day period . Subjects hemoglobin &lt; 12 g/dL . The subject 's systolic blood pressure outside range 90140mmHg , diastolic blood pressure outside range 4590mmHg heart rate outside range 50100bpm female subject 45100 bpm male subject . ECG within protocol limit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>GSK1349572</keyword>
	<keyword>moxifloxacin</keyword>
	<keyword>Avelox</keyword>
	<keyword>QTc</keyword>
</DOC>